Jupiter Asset Management Ltd. Sells 128,669 Shares of CareDx, Inc. $CDNA

Jupiter Asset Management Ltd. cut its holdings in CareDx, Inc. (NASDAQ:CDNA) by 64.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 69,715 shares of the company’s stock after selling 128,669 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in CareDx were worth $1,014,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Cetera Trust Company N.A grew its holdings in CareDx by 11.2% during the 2nd quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock worth $238,000 after acquiring an additional 1,225 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of CareDx by 5.9% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 22,509 shares of the company’s stock valued at $440,000 after purchasing an additional 1,264 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of CareDx by 4.8% during the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after purchasing an additional 1,280 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of CareDx by 12.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 11,885 shares of the company’s stock valued at $232,000 after purchasing an additional 1,293 shares in the last quarter. Finally, Swiss National Bank raised its position in CareDx by 2.0% in the 2nd quarter. Swiss National Bank now owns 100,600 shares of the company’s stock worth $1,966,000 after purchasing an additional 2,000 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CDNA. Craig Hallum lowered CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective on the stock. in a research report on Tuesday, January 6th. Wells Fargo & Company raised their price target on CareDx from $14.00 to $18.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Zacks Research upgraded CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th. Wall Street Zen downgraded shares of CareDx from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CareDx in a research note on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, CareDx currently has an average rating of “Hold” and a consensus target price of $26.67.

Insider Activity at CareDx

In related news, CEO John Walter Hanna, Jr. sold 19,280 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total value of $407,964.80. Following the sale, the chief executive officer directly owned 597,405 shares in the company, valued at $12,641,089.80. This trade represents a 3.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders sold 29,636 shares of company stock valued at $625,949. Corporate insiders own 4.40% of the company’s stock.

CareDx Trading Down 5.4%

NASDAQ CDNA opened at $18.80 on Monday. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $24.02. The stock has a 50-day simple moving average of $19.71 and a 200 day simple moving average of $16.64. The company has a market capitalization of $966.88 million, a PE ratio of 15.80 and a beta of 2.51.

CareDx Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.